Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hu1D10 in Recurrent Hodgkin's Disease
NCT00055783Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jul 2002
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of apolizumab in Hodgkin lymphoma (HL), sponsored by Stanford University. Started Jul 2002; status: completed.
02
Drugs
apolizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00055783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055783.